TY - JOUR
T1 - Diabetes mellitus and prevention of late myocardial infarction after coronary Stenting in the randomized dual Antiplatelet therapy study
AU - Meredith, Ian T.
AU - Tanguay, Jean François
AU - Kereiakes, Dean J.
AU - Cutlip, Donald E.
AU - Yeh, Robert W.
AU - Garratt, Kirk N.
AU - Lee, David P.
AU - Steg, P. Gabriel
AU - Weaver, W. Douglas
AU - Holmes, David R.
AU - Brindis, Ralph G.
AU - Trebacz, Jaroslaw
AU - Massaro, Joseph M.
AU - Hsieh, Wen Hua
AU - Mauri, Laura
N1 - Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/5/3
Y1 - 2016/5/3
N2 - Background - Patients with diabetes mellitus (DM) are at high risk for recurrent ischemic events after coronary stenting. We assessed the effects of continued thienopyridine among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis. Methods and Results - After coronary stent placement and 12 months treatment with open-label thienopyridine plus aspirin, 11 648 patients free of ischemic or bleeding events and who were medication compliant were randomly assigned to continued thienopyridine or placebo, in addition to aspirin, for 18 more months. After randomization, patients with DM (n=3391), in comparison with patients without DM (n=8257), had increased composite outcome of death, myocardial infarction (MI), or stroke (6.8% versus 4.3%, P<0.001), increased death (2.5% versus 1.4%, P<0.001), and MI (4.2% versus 2.6%, P<0.001). Among patients with DM, in a comparison of continued thienopyridine versus placebo, rates of stent thrombosis were 0.5% versus 1.1%, P=0.06, and rates of MI were 3.5% versus 4.8%, P=0.058; and among patients without DM the rates were 0.4% versus 1.4%, P<0.001 (stent thrombosis, P interaction=0.21) and 1.6% versus 3.6%, P<0.001 (MI, P interaction=0.02). Bleeding risk with continued thienopyridine was similar among patients with or without DM (interaction P=0.61). Conclusions - In patients with DM, continued thienopyridine beyond 1 year after coronary stenting is associated with reduced risk of MI, although this benefit is attenuated in comparison with patients without DM. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
AB - Background - Patients with diabetes mellitus (DM) are at high risk for recurrent ischemic events after coronary stenting. We assessed the effects of continued thienopyridine among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis. Methods and Results - After coronary stent placement and 12 months treatment with open-label thienopyridine plus aspirin, 11 648 patients free of ischemic or bleeding events and who were medication compliant were randomly assigned to continued thienopyridine or placebo, in addition to aspirin, for 18 more months. After randomization, patients with DM (n=3391), in comparison with patients without DM (n=8257), had increased composite outcome of death, myocardial infarction (MI), or stroke (6.8% versus 4.3%, P<0.001), increased death (2.5% versus 1.4%, P<0.001), and MI (4.2% versus 2.6%, P<0.001). Among patients with DM, in a comparison of continued thienopyridine versus placebo, rates of stent thrombosis were 0.5% versus 1.1%, P=0.06, and rates of MI were 3.5% versus 4.8%, P=0.058; and among patients without DM the rates were 0.4% versus 1.4%, P<0.001 (stent thrombosis, P interaction=0.21) and 1.6% versus 3.6%, P<0.001 (MI, P interaction=0.02). Bleeding risk with continued thienopyridine was similar among patients with or without DM (interaction P=0.61). Conclusions - In patients with DM, continued thienopyridine beyond 1 year after coronary stenting is associated with reduced risk of MI, although this benefit is attenuated in comparison with patients without DM. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00977938.
KW - diabetes mellitus
KW - dual antiplatelet therapy
KW - myocardial infarction
KW - stents
UR - http://www.scopus.com/inward/record.url?scp=84961391362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961391362&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.115.016783
DO - 10.1161/CIRCULATIONAHA.115.016783
M3 - Article
C2 - 26994121
AN - SCOPUS:84961391362
SN - 0009-7322
VL - 133
SP - 1772
EP - 1782
JO - Circulation
JF - Circulation
IS - 18
ER -